



Small Doses.....

by

Mike Petry, MS, RPh

Clinical Pharmacist

New Drugs for 2009

The United States Food and Drug Administration (FDA) approved a total of 37 drugs, vaccines, and blood products in 2009. Listed below is a selection of these new products that health care providers may encounter in the near future.

Abobotulinumtoxin A for injection (Dysport[®]), for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain and for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age.

Antithrombin, recombinant for infusion (Atryn[®]), for the prevention of perioperative and peripartum thromboembolic events in patients with hereditary antithrombin deficiency.

Artemether–lumefantrine tablets (Coartem[®]), for the treatment of acute, uncomplicated malaria infections in adults and children.

Asenapine tablets (Saphris[®]), for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder in adults.

Interferon beta-1b for injection (Extavia[®]), for the treatment of relapsing forms of multiple sclerosis.

Benzyl alcohol lotion (Ulesfia[®]), for the treatment of head lice infestation.

Bepotastine ophthalmic solution (Bepreve[®]), for the treatment of ocular itching associated with allergic conjunctivitis.

Besifloxacin ophthalmic suspension (Besivance[®]), for the treatment of bacterial conjunctivitis.

C1 esterase inhibitor, human for infusion (Berinert[®]), for the treatment of acute abdominal or facial attacks of hereditary angioedema in adults and adolescents.

Canakinumab injection (Ilaris[®]), for the treatment of familial cold autoinflammatory syndrome and Muckle-Wells syndrome.

Colchicine tablets (Colcrys[®]), for the treatment of gout flares and familial Mediterranean fever.

Dronedarone tablets (Multaq[®]), for the maintenance of normal heartbeat in certain patients with a history of paroxysmal or persistent atrial fibrillation or atrial flutter.

Ecallantide injection (Kalbitor[®]), for the treatment of acute attacks of hereditary angioedema.

Everolimus tablets (Afinitor[®]), for the treatment of advanced renal cell carcinoma.



Febuxostat tablets (Uloric[®]),
for the reduction of elevated serum uric acid levels in patients with gout.

Ferumoxytol injection (Feraheme[®]), for the treatment of iron deficiency anemia in adults with chronic kidney disease.

Fibrinogen concentrate, human for infusion (Riastap[®]), for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency.

Golimumab injection (Simponi[®]), for the once-monthly treatment of adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, or active ankylosing spondylitis.

Haemophilus b conjugate vaccine (Hiberix[®]), for the prevention of invasive disease caused by *Haemophilus influenzae* type b in children 15 months through 4 years of age.

Human papillomavirus bivalent vaccine, recombinant for injection (Cervarix[®]), to protect against cancers caused by infection with human papillomavirus types 16 and 18.

Iloperidone tablets (Fanapt[®]), for the acute treatment of schizophrenia in adults.

Influenza virus vaccine, inactivated (Agriflu[®]), for active immunization of adults against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.

Immune globulin, human
for injection (Gammaplex[®]),
for the treatment of patients
with primary humoral immunodeficiency.

Japanese encephalitis vaccine, inactivated (Ixiaro[®]), for the prevention of disease caused by Japanese encephalitis virus in adults.

Milnacipran tablets (Savella[®]), for the treatment of fibromyalgia.

Ofatumumab for infusion (Arzerra[®]), for the treatment of chronic lymphocytic leukemia in patients whose cancer does not respond to other chemotherapy.

Pancrelipase capsules (Creon[®]), for the treatment of pancreatic insufficiency in adults and children with exocrine pancreatic insufficiency resulting from cystic fibrosis or other conditions.

Pazopanib tablets (Votrient[®]), for the treatment of advanced renal cell carcinoma.

Pitavastatin calcium tablets (Livalo[®]), for the improvement of cholesterol levels in patients who have not been able to control their dyslipidemia through diet and exercise.

Pralatrexate injection (Foloty[®]n), for the treatment of peripheral T-cell lymphoma in patients whose disease has returned or not responded to previous therapy.

Prasugrel tablets (Effient[®]), to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome who are undergoing a catheter-based procedure to reopen an occluded coronary artery.

Romidepsin for injection (Istodax[®]), for the treatment of cutaneous T-cell lymphoma in patients who have already received at least one systemic therapy for the disease.

Saxagliptin tablets (Onglyza[®]), to help control blood glucose concentrations in patients with type 2 diabetes.

Telavancin for injection (Vibativ[®]), for the treatment of complicated skin and skin-structure infections in adults.

Tolvaptan tablets (Samsca[®]), for the treatment of patients with hypervolemic or euvolemic hyponatremia.

Ustekinumab for injection (Stelara[®]), for the treatment of severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy.

Vigabatrin tablets and solution (Sabril[®]), for the treatment of infantile spasms and as add-on therapy for the treatment of complex partial seizures in adults.

Nursing in-service

Date

